TG THERAPEUTICS, INC. (TGTX)
$56.28-$0.19 (-0.34%) Latest sessionExtended Hours
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 5,000 | $275K |
| Bona-fide gift | 3 | 6,050 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
19 Form 4 filings on record, the earliest from Nov 7, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Laurence N. Charney - Director | Open-market sale | Common Stock | 5,000 | $54.96 | $275K | |
| Laurence N. Charney - Director | Gift | Common Stock | 5,100 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 500 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 450 | $0.00 | - | |
| Sagar Lonial - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Daniel Hume - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Kenneth Hoberman - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Yann Echelard - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Laurence N. Charney - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 30,000 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 13,197 | $0.00 | - | |
| Yann Echelard - Director | Open-market sale | Common Stock | 5,000 | $32.57 | $163K | |
| Michael S. Weiss - Officer | Gift | Common Stock | 3,865,126 | $0.00 | - | |
| Michael S. Weiss - Officer | Gift | Common Stock | 803,717 | $0.00 | - | |
| Sagar Lonial - Director | Open-market sale | Common Stock | 20,852 | $32.24 | $672K | |
| Laurence N. Charney - Director | Grant or award | Common Stock | 21,408 | $0.00 | - | |
| Kenneth Hoberman - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Daniel Hume - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Sagar Lonial - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Yann Echelard - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Yann Echelard - Director | Open-market sale | Common Stock | 10,000 | $36.94 | $369K | |
| Laurence N. Charney - Director | Open-market sale | Common Stock | 25,000 | $30.20 | $755K | |
| Laurence N. Charney - Director | Gift | Common Stock | 5,000 | $0.00 | - | |
| Sagar Lonial - Director | Open-market sale | Common Stock | 5,000 | $30.44 | $152K | |
| Yann Echelard - Director | Open-market sale | Common Stock | 20,000 | $24.48 | $490K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Charney Laurence N | Director | 5,000 | $275K | View on EDGAR |
TG THERAPEUTICS, INC. (TGTX) had 2 insider filings in the last 90 days, with the most recent on 2026-09-14. The full record for TGTX runs to 19 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TGTX were filed in the last 90 days.
1 insider sale of TGTX was filed in the last 90 days, totaling $275K.
This page tracks TGTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TGTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
